<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00398398</url>
  </required_header>
  <id_info>
    <org_study_id>AMC-ONCGI-0603</org_study_id>
    <secondary_id>EMR 62202-723,OXALI_L_01600</secondary_id>
    <nct_id>NCT00398398</nct_id>
  </id_info>
  <brief_title>Study of XELOX With Cetuximab in Advanced Gastric Cancer</brief_title>
  <official_title>A Prospective Phase II Study of Cetuximab (Erbitux®) in Combination With XELOX [XELoda® (Capecitabine) and OXaliplatin] in Patients With Advanced Gastric Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Asan Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Asan Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The combination of capecitabine and oxaliplatin as 'backbone' regimen, adding a newer
      biologic agent, cetuximab, is a reasonable strategy of further chemotherapy development in
      advanced gastric cancer, which is the investigators study rationale.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      There is presently no chemotherapy regimen considered to be the global standard of care for
      patients with AGC, and there is still a need for new agents and/or regimens to improve the
      efficacy and safety of chemotherapy in advanced stomach cancers.

      The combination of 5-fluorouracil plus cisplatin (FP) has been widely used for the first-line
      treatment of advanced gastric cancer in many countries.

      Randomized phase III trial investigating capecitabine plus cisplatin(XP) versus FP showed XP
      is at least as good as FP with improved patients' preference.

      A Phase II study of capecitabine plus oxaliplatin (XELOX) was conducted in our study group.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2006</start_date>
  <completion_date type="Actual">September 2008</completion_date>
  <primary_completion_date type="Actual">September 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Response Rate</measure>
    <time_frame>6 months</time_frame>
    <description>Tumor response was evaluated every two cycles by CT scans and other indicated methods, and the patients with complete or partial response required a confirmatory response evaluation at least 4 weeks later. Patients without confirmatory evaluation were not regarded as responders.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free Survival</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity Profile</measure>
    <time_frame>1 years</time_frame>
    <description>Number of patients who experienced toxicity from study treatment to evaluate the safety and tolerability of XELOX plus Cetuximab</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">44</enrollment>
  <condition>Gastric Cancer</condition>
  <arm_group>
    <arm_group_label>Capecitbine, oxaliplatin, cetuximab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Capecitbine, oxaliplatin and cetuximab every three week; Capecitabine 1,000 mg/m2 was administered twice daily on days 1-14. Oxaliplatin 130 mg/m2 i.v. for 2 h was given on day 1 after cetuximab infusion. Cetuximab at an initial loading dose of 400 mg/m2 i.v. for 2 h and, thereafter, maintenance dose of 250 mg/m2 for 1 h every week.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine, Oxaliplatin, Cetuximab</intervention_name>
    <description>Xelox(Capecitbine, Oxaliplatin) and Cetuximab every three week; Capecitabine 1,000 mg/m2 was administered twice daily on days 1-14. Oxaliplatin 130 mg/m2 i.v. for 2 h was given on day 1 after cetuximab infusion. Cetuximab at an initial loading dose of 400 mg/m2 i.v. for 2 h and, thereafter, maintenance dose of 250 mg/m2 for 1 h every week.</description>
    <arm_group_label>Capecitbine, oxaliplatin, cetuximab</arm_group_label>
    <other_name>xeloda, oxalitin, Erbitux</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Having given signed written informed consent

          -  Patients must have histologically or cytologically documented stomach adenocarcinoma
             including adenocarcinoma of the esophagogastric junction.

          -  Patients must have unresectable metastatic disease or recurrent disease after curative
             surgical resection with uni-dimensionally measurable disease according to RECIST (at
             least longest diameter 1 cm on computed tomography scan, or at least 2 cm on chest
             x-ray or physical examination

          -  Age 18 to 70 years old

          -  Estimated life expectancy of more than 3 months

          -  ECOG performance status &lt; 2 (See Appendix E)

          -  Adequate bone marrow function (WBC&gt;3,000/µL, ANC&gt;1,500/µL, and platelets&gt;100,000/µL,
             Hb&gt;8g/dl)

          -  Adequate kidney function (creatinine&lt;1.5 mg/dL)

          -  Adequate liver function [bilirubin&lt; 2.0 mg/dL, transaminases levels&lt;3 times the Upper
             Normal Value (5 times for patients with liver metastasis)]

          -  Prothrombin time not less than 50% of Lower Normal Value

          -  No prior chemotherapy

          -  No prior radiation therapy

          -  Patients must not have psychological, familial, sociological or geographical
             conditions which do not permit medical follow-up and compliance with this study.

          -  Women of childbearing potential must have a negative serum HCG pregnancy test on
             admission. Men and women of reproductive potential must have agreed to use an
             effective method of contraception while on treatment and for 6 months after study
             treatment.

        Exclusion Criteria:

          -  Past or concurrent history of neoplasm other than gastric adenocarcinoma within the
             last five years, except for curatively treated non-melanoma skin cancer or in situ
             carcinoma of the cervix uteri.

          -  Central nervous system (CNS) metastases.

          -  Major surgical procedure, open biopsy, or significant traumatic injury within 28 days
             prior to study treatment start

          -  Gastric outlet obstruction, intestinal obstruction and obvious peritoneal seeding.

          -  Evidence of serious gastrointestinal bleeding.

          -  The patient has bony lesions as the sole evaluable disease.

          -  Pregnant or lactating women, women of childbearing potential not employing adequate
             contraception.

          -  Patients with sensory neuropathy (grade&gt; 1 according to NCI CTCAE v. 3.0).

          -  Hypersensitivity to any of the study drugs or ingredients.

          -  Other serious illness or medical conditions that would not allow study participation
             in the best interest of the patient as decided by the investigator.

          -  Unstable cardiac disease despite treatment, myocardial infarction within 6 months
             prior to study entry.

          -  History of significant neurologic or psychiatric disorders including dementia or
             seizures.

          -  Active uncontrolled infection.

          -  Pre-existing clinically significant diarrhea.

          -  Unstable diabetes mellitus.

          -  Severe hypercalcemia of &gt; 12 mg/dL and uncontrolled with bisphosphonates.

          -  Active disseminated intravascular coagulation.

          -  Concurrent treatment with corticosteroids (or equivalent) except as use for the
             prophylactic medication regimen, treatment of acute hypersensitivity reactions or
             nausea, or unless chronic treatment (initiated &gt; 6 months prior to study entry) at low
             dose (&lt;20 mg methyl prednisolone or equivalent).

          -  Concomitant or administration of any other experimental drug under investigation
             within 4 weeks before the study.

          -  Concomitant or previous hormonal therapy, or immunotherapy.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yoon-Koo Kang, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Asan Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Korea Cancer Center Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 9, 2006</study_first_submitted>
  <study_first_submitted_qc>November 9, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 10, 2006</study_first_posted>
  <results_first_submitted>December 15, 2013</results_first_submitted>
  <results_first_submitted_qc>October 6, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 2, 2015</results_first_posted>
  <last_update_submitted>July 13, 2017</last_update_submitted>
  <last_update_submitted_qc>July 13, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Asan Medical Center</investigator_affiliation>
    <investigator_full_name>Yoon-Koo Kang</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>gastric cancer</keyword>
  <keyword>chemotherapy</keyword>
  <keyword>cetuximab</keyword>
  <keyword>capecitabine</keyword>
  <keyword>oxaliplatin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Cetuximab</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Xelox Plus Cetuximab</title>
          <description>Capecitabine, oxaliplatin and cetuximab
cetuximab : initial loading dose of 400 mg/m2, maintenance dose of 250 mg/m2 (every week) Oxaliplatin : 130 mg/m2 (every 3 weeks) capecitabine :1,000 mg/m2 (days 1–14)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="44"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="44"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Xelox Plus Cetuximab</title>
          <description>Capecitabine, oxaliplatin and cetuximab</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="44"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57.5" lower_limit="36" upper_limit="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Korea, Republic of</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Overall Response Rate</title>
        <description>Tumor response was evaluated every two cycles by CT scans and other indicated methods, and the patients with complete or partial response required a confirmatory response evaluation at least 4 weeks later. Patients without confirmatory evaluation were not regarded as responders.</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Xelox Plus Cetuximab</title>
            <description>Capecitabine, oxaliplatin and cetuximab</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Response Rate</title>
          <description>Tumor response was evaluated every two cycles by CT scans and other indicated methods, and the patients with complete or partial response required a confirmatory response evaluation at least 4 weeks later. Patients without confirmatory evaluation were not regarded as responders.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progression-free Survival</title>
        <time_frame>1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Xelox Plus Cetuximab</title>
            <description>Capecitabine, oxaliplatin and cetuximab</description>
          </group>
        </group_list>
        <measure>
          <title>Progression-free Survival</title>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.5" lower_limit="4.9" upper_limit="8.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival</title>
        <time_frame>1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Xelox Plus Cetuximab</title>
            <description>Capecitabine, oxaliplatin and cetuximab</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival</title>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.8" lower_limit="6.7" upper_limit="16.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Toxicity Profile</title>
        <description>Number of patients who experienced toxicity from study treatment to evaluate the safety and tolerability of XELOX plus Cetuximab</description>
        <time_frame>1 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Xelox Plus Cetuximab</title>
            <description>Capecitabine, oxaliplatin and cetuximab</description>
          </group>
        </group_list>
        <measure>
          <title>Toxicity Profile</title>
          <description>Number of patients who experienced toxicity from study treatment to evaluate the safety and tolerability of XELOX plus Cetuximab</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 year after completion of study treatment. If patients received another treatment, toxicity assessment was not done further.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Xelox Plus Cetuximab</title>
          <description>Capecitabine, oxaliplatin and cetuximab</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>NCI_CTCAE_v3.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Mood disorder</sub_title>
                <description>Mood fluctuation during treatment. But this was assessed as unlikely to be related to study treatment.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>NCI_CTCAE_v3.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="44" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Elevated Aspartate aminotransferase</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Elevated alanine transferase</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Elevated bilirubin</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Infusion reaction</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Sensory neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Hand-foot syndrome</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Acneiform rash</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Yoon-Koo Kang</name_or_title>
      <organization>Asan Medical Center</organization>
      <phone>+82-2-3010-3210</phone>
      <email>ykkang@amc.seoul.kr</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

